Biomarkers predictive of exacerbations in the SPIROMICS and COPDGene cohorts

American Journal of Respiratory and Critical Care Medicine

Volumn 195, Issue 4, 2017, Pages 473-481

  Keene, Jason D ^a   Jacobson, Sean ^b   Kechris, Katerina ^c   Kinney, Gregory L ^c   Foreman, Marilyn G ^d   Doerschuk, Claire M ^e   Make, Barry J ^b   Curtis, Jeffrey L ^f,g   Rennard, Stephen I ^h   Barr, R Graham ⁱ   Bleecker, Eugene R ^j   Kanner, Richard E ^k   Kleerup, Eric C ^l   Hansel, Nadia N ^m   Woodruff, Prescott G ⁿ   Han, MeiLan K ^f   Paine, Robert ^k   Martinez, Fernando J ^o   Bowler, Russell P ^b   O'Neal, Wanda K ^e  

^a UNIVERSITY OF COLORADO   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c Food Science and Human Nutrition   (United States)

^d MOREHOUSE SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^g VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^h UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

ⁱ Department of Medicine   (United States)

^j WAKE FOREST SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o WEILL CORNELL MEDICAL CENTER   (United States)

more..

Author keywords

Biomarker; COPD; Exacerbation

Indexed keywords

A2M PROTEIN; ALPHA 2 MACROGLOBULIN; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CCL16 PROTEIN; CXCL9 CHEMOKINE; DCN PROTEIN; DECORIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN M; INTERLEUKIN 16; INTERLEUKIN 18 BINDING PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDNISONE; PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SERPINA1 PROTEIN; SERPINE1 PROTEIN; SPINK1 PROTEIN; UNCLASSIFIED DRUG; ANTIBIOTIC AGENT; BRONCHODILATING AGENT; C REACTIVE PROTEIN; C-C MOTIF CHEMOKINE 18; CORTICOSTEROID; EOTAXIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FERRITIN; FIBRINOGEN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MATRIPTASE; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 4; PROSTATE SPECIFIC ANTIGEN; TRYPSIN INHIBITOR;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; AIRWAY OBSTRUCTION; BODY MASS; CHRONIC BRONCHITIS; COMPUTER ASSISTED TOMOGRAPHY; EMERGENCY WARD; EMPHYSEMA; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; GENETIC EPIDEMIOLOGY; HEALTH CARE COST; HOSPITALIZATION; LEUKOCYTE COUNT; LIMIT OF QUANTITATION; MIDDLE AGED; MORTALITY; OXYGEN CONSUMPTION; OXYGEN SATURATION; PEOPLE BY SMOKING STATUS; PHYSIOLOGY; RESPIRATORY CARE; RETROSPECTIVE STUDY; SPIROMETRY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SUBPOPULATION AND INTERMEDIATE OUTCOME CHRONIC OBSTRUCTIVE LUNG DISEASE STUDY; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SMOKING;

BIOMARKERS; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SMOKING;

EID: 85014916073     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201607-1330OC     Document Type: Article

References (42)

1. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
2. Agustí A, Faner R. Systemic inflammation and comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2012; 9:43-46.
3. Bowler RP, Kim V, Regan E, Williams AA, Santorico SA, Make BJ, Lynch DA, Hokanson JE, Washko GR, Bercz P, et al.; COPDGene investigators. Prediction of acute respiratory disease in current and former smokers with and without COPD. Chest 2014; 146: 941-950.
4. Donaldson GC, Wedzicha JA. COPD exacerbations. 1: Epidemiology. Thorax 2006; 61:164-168.
5. Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, Lomas DA. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 2013; 68:670-676.
6. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 2013; 309:2353-2361.
7. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R; Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011; 12:146.
8. Ozyurek BA, Ulasli SS, Bozbas SS, Bayraktar N, Akcay S. Value of serum and induced sputum surfactant protein-D in chronic obstructive pulmonary disease. Multidiscip Respir Med 2013; 8:36.
9. Minas M, Mystridou P, Georgoulias P, Pournaras S, Kostikas K, Gourgoulianis KI. Fetuin-A is associated with disease severity and exacerbation frequency in patients with COPD. COPD 2013; 10:28-34.
10. Kirdar S, Serter M, Ceylan E, Sener AG, Kavak T, Karadaǧ F. Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease. Scand J Clin Lab Invest 2009; 69:219-224.
11. Miller BE, Tal-Singer R, Rennard SI, Furtwaengler A, Leidy N, Lowings M, Martin UJ, Martin TR, Merrill DD, Snyder J, et al.; Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium. Plasma fibrinogen qualification as a drug development tool in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2016; 193:607-613.
12. Couper D, LaVange LM, Han M, Barr RG, Bleecker E, Hoffman EA, Kanner R, Kleerup E, Martinez FJ, Woodruff PG, et al.; SPIROMICS Research Group. Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax 2014; 69:491-494.
13. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946.
14. Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, Curran-Everett D, Silverman EK, Crapo JD. Genetic epidemiology of COPD (COPDGene) study design. COPD 2010; 7:32-43.
15. Carolan BJ, Kim YI, Williams AA, Kechris K, Lutz S, Reisdorph N, Bowler RP. The association of adiponectin with computed tomography phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188:561-566.
16. O'Neal WK, Anderson W, Basta PV, Carretta EE, Doerschuk CM, Barr RG, Bleecker ER, Christenson SA, Curtis JL, Han MK, et al.; SPIROMICS Investigators. Comparison of serum, EDTA plasma and P100 plasma for Luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study. J Transl Med 2014; 12:9.
17. Carolan BJ, Hughes G, Morrow J, Hersh CP, O'Neal WK, Rennard S, Pillai SG, Belloni P, Cockayne DA, Comellas AP, et al. The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes. Respir Res 2014; 15:127.
18. Sun W, Kechris K, Jacobson S, Drummond MB, Hawkins GA, Yang J, Chen TH, Quibrera PM, Anderson W, Barr RG, et al.; SPIROMICS Research Group; COPDGene Investigators. Common genetic polymorphisms influence blood biomarker measurements in COPD. PLoS Genet 2016; 12:e1006011.
19. Fabbri LM, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J 2003; 22:1-2.
20. Wan ES, Castaldi PJ, Cho MH, Hokanson JE, Regan EA, Make BJ, Beaty TH, Han MK, Curtis JL, Curran-Everett D, et al.; COPDGene Investigators. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. Respir Res 2014; 15:89.
21. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-1327.
22. Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, Hersh CP, Stinson D, Silverman EK, Criner GJ; COPDGene Investigators. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest 2011; 140:626-633.
23. Team RCR. A language and environment for statistical computing. 3.2.4 ed. Vienna, Austria: R Foundation for Statistical Computing; 2015.
24. Cameron AC, Trivedi PK. Regression analysis of count data. Cambridge, UK: Cambridge University Press; 1998.
25. Zeileis A, Kleiber C, Jackman S. Regression models for count data in R. J Stat Softw 2008; 27:1-25.
26. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Statist 1982; 10:1100-1120.
27. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.
28. Cragg JG, Uhler RS. The demand for automobiles. Can J Econ 1970; 3: 386-406.
29. Regan EA, Lynch DA, Curran-Everett D, Curtis JL, Austin JH, Grenier PA, Kauczor HU, Bailey WC, DeMeo DL, Casaburi RH, et al.; Genetic Epidemiology of COPD Investigators. Clinical and radiologic disease in smokers with normal spirometry. JAMA Intern Med 2015; 175: 1539-1549.
30. Woodruff PG, Barr RG, Bleecker E, Christenson SA, Couper D, Curtis JL, Gouskova NA, Hansel NN, Hoffman EA, Kanner RE, et al.; SPIROMICS Research Group. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med 2016; 374:1811-1821.
31. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:867-874.
32. Karadag F, Karul AB, Cildag O, Yilmaz M, Ozcan H. Biomarkers of systemic inflammation in stable and exacerbation phases of COPD. Lung 2008; 186:403-409.
33. Perera WR, Hurst JR, Wilkinson TM, Sapsford RJ, Müllerova H, Donaldson GC, Wedzicha JA. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007; 29:527-534.
34. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3: 435-442.
35. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med 2016; 193:965-974.
36. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359:2355-2365.
37. Song Q, Christiani DC, Xiaorong Wang, Ren J. The global contribution of outdoor air pollution to the incidence, prevalence, mortality and hospital admission for chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Environ Res Public Health 2014; 11:11822-11832.
38. Almagro P, Hernandez C, Martinez-Cambor P, Tresserras R, Escarrabill J. Seasonality, ambient temperatures and hospitalizations for. acute exacerbation of COPD: a population-based study in a metropolitan area. Int J Chron Obstruct Pulmon Dis 2015; 10:899-908.
39. Tseng CM, Chen YT, Ou SM, Hsiao YH, Li SY, Wang SJ, Yang AC, Chen TJ, Perng DW. The effect of cold temperature on increased exacerbation of chronic obstructive pulmonary disease: a nationwide study. PLoS One 2013; 8:e57066.
40. Marcun R, Stankovic I, Vidakovic R, Farkas J, Kadivec S, Putnikovic B, Ilic I, Neskovic AN, Lainscak M. Prognostic implications of heart failure with preserved ejection fraction in patients with an exacerbation of chronic obstructive pulmonary disease. Intern Emerg Med 2016; 11:519-527.
41. Frei A, Siebeling L, Wolters C, Held L, Muggensturm P, Strassmann A, Zoller M, Riet GT, Puhan MA. The inaccuracy of patient recall for COPD exacerbation rate estimation and its implications: results from central adjudication. Chest 2016; 150:860-868.
42. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005-1012.